Acute-phase proteins as indicators of disease severity and mortality in COVID-19 patients.
Acute-phase proteins
COVID-19
Cytokine storm
Disease severity
Oxygen therapy
Prognostic marker
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 Sep 2024
02 Sep 2024
Historique:
received:
25
03
2024
accepted:
27
08
2024
medline:
3
9
2024
pubmed:
3
9
2024
entrez:
2
9
2024
Statut:
epublish
Résumé
The aim of the study was to conduct of relationship of acute-phase proteins (APPs) with the severity of COVID-19 defined by National Institutes of Health and according to the criteria of MEWS scale, with the presence of a cytokine storm, oxygen therapy and patient survival. We enrolled 96 patients with COVID-19 and 30 healthy people. The samples were taken on the day of admission and after 9 days on average. Not only commonly used APPs such as CRP, procalcitonin and ferritin and also rarely assayed proteins such as transferrin, haptoglobin, α1-acid glycoprotein and α1-antitrypsin, were tested in the study. The levels of APPs depends on the severity of COVID-19 disease, on the presence of cytokine storm and used oxygen therapy. The greatest APPs changes occurred in the most advanced form of the disease, with the presence of a cytokine storm and the most intense oxygen therapy. The results obtained from MEWS scale were not consistent with National Institutes of Health scores. Studies in the second samples showed the quenching of the acute phase reactions and the effectiveness of oxygen therapy. Only two of the examined APPs i.e. procalcitonin and transferrin, differed between surviving and non-surviving patients, and these two predispose to the role of prognostic factors in Covid-19. In conclusion, the concentration of not all acute-phase proteins depends on the severity of COVID-19 disease, presence of cytokine storm, the used of oxygen therapy and only some of them (procalcitonin and transferrin) are related to the survival outcomes. Of the newly tested acute-phase proteins, only transferrin shows significance as a marker of disease severity and mortality in COVID-19 disease.
Identifiants
pubmed: 39223203
doi: 10.1038/s41598-024-71325-2
pii: 10.1038/s41598-024-71325-2
doi:
Substances chimiques
Acute-Phase Proteins
0
Biomarkers
0
Procalcitonin
0
Transferrin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20360Informations de copyright
© 2024. The Author(s).
Références
Li, L. & Chen, C. Contribution of acute-phase reaction proteins to the diagnosis and treatment of 2019 novel coronavirus disease (COVID-19). Epidemiol. Infect. 148, e164 (2020).
doi: 10.1017/S095026882000165X
pubmed: 32713370
Ehlting, C., Wolf, S. D. & Bode, J. G. Acute-phase protein synthesis: A key feature of innate immune functions of the liver. Biol. Chem. 402, 1129–1145 (2021).
doi: 10.1515/hsz-2021-0209
pubmed: 34323429
Dowton, S. B. & Colten, H. R. Acute phase reactants in inflammation and infection. Semin. Hematol. 25, 84–90 (1988).
pubmed: 2455348
Kushner, I., Gewurz, H. & Benson, M. D. C-reactive protein and the acute-phase response. J. Lab. Clin. Med. 97, 739–749 (1981).
pubmed: 7229508
Ingenbleek, Y. & Young, V. Transthyretin (prealbumin) in health and disease: Nutritional implications. Annu. Rev. Nutr. 14, 495–533 (1994).
doi: 10.1146/annurev.nu.14.070194.002431
pubmed: 7946531
Fazal, M. C-reactive protein a promising biomarker of COVID-19 severity. Korean J. Clin. Lab. Sci. 53, 201–207 (2021).
doi: 10.15324/kjcls.2021.53.3.201
Luan, Y. Y., Yin, C. H. & Yao, Y. M. Update advances on C-reactive protein in COVID-19 and other viral infections. Front. Immunol. 12, 720363 (2021).
doi: 10.3389/fimmu.2021.720363
pubmed: 34447386
pmcid: 8382792
Kappert, K., Jahić, A. & Tauber, R. Assessment of serum ferritin as a biomarker in COVID-19: bystander or participant? Insights by comparison with other infectious and non-infectious diseases. Biomarkers 25, 616–625 (2020).
doi: 10.1080/1354750X.2020.1797880
pubmed: 32700561
Huang, I., Pranata, R., Lim, M. A., Oehadian, A. & Alisjahbana, B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: A meta-analysis. Ther. Adv. Respir. Dis. 14, 1753466620937175 (2020).
doi: 10.1177/1753466620937175
pubmed: 32615866
pmcid: 7336828
Liu, F. et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J. Clin. Virol. 127, 104370 (2020).
doi: 10.1016/j.jcv.2020.104370
pubmed: 32344321
pmcid: 7194648
Topcu, H. & Arik, Y. E. The importance of D-dimer, ferritin, CRP and lymphocyte values in determining mortality in COVID-19 disease in Turkey. Clin. Lab. https://doi.org/10.7754/Clin.Lab.2021.210720 (2022).
doi: 10.7754/Clin.Lab.2021.210720
pubmed: 35975538
Yormaz, B. et al. The evaluation of prognostic value of acute phase reactants in the COVID-19. Bratisl. Lek. Listy 121, 628–633 (2020).
pubmed: 32990010
Sayit, A. T., Elmali, M., Deveci, A. & Gedikli, O. Relationship between acute phase reactants and prognosis in patients with or without COVID-19 pneumonia. Rev. Inst. Med. Trop. Sao Paulo 63, e51 (2021).
doi: 10.1590/s1678-9946202163051
pubmed: 34190953
pmcid: 8231967
Giri, N. C. Role of Transferrin in Iron Metabolism [Internet]. Iron Metabolism—A Double-Edged Sword (IntechOpen, 2022). https://doi.org/10.5772/intechopen.100488 .
doi: 10.5772/intechopen.100488
Kim, J. H. Clinical utility of procalcitonin on antibiotic stewardship: A narrative review. Infect. Chemother. 54, 610–620 (2022).
doi: 10.3947/ic.2022.0162
pubmed: 36596677
pmcid: 9840962
Baj, J. et al. COVID-19: Specific and non-specific clinical manifestations and symptoms: The current state of knowledge. J. Clin. Med. 9, 1753 (2020).
doi: 10.3390/jcm9061753
pubmed: 32516940
pmcid: 7356953
Stenhouse, C., Coates, S., Tivey, M., Allsop, P. & Parker, T. Prospective evaluation of a modified early warning score to aid earlier detection of patients developing critical illness on a general surgical ward. Br. J. Anaesth. 84, 663P (1999).
doi: 10.1093/bja/84.5.663
Subbe, C. P., Kruger, M., Rutherford, P. & Gemmel, L. Validation of a modified early warning score in medical admissions. QJM 94, 521–526 (2001).
doi: 10.1093/qjmed/94.10.521
pubmed: 11588210
Ferrara, J. L., Abhyankar, S. & Gilliland, D. G. Cytokine storm of graft-versus-host disease: A critical effector role for interleukin-1. Transplant. Proc. 25(1 Pt 2), 1216–1217 (1993).
pubmed: 8442093
Gubernatorova, E. O., Gorshkova, E. A., Polinova, A. I. & Drutskaya, M. S. IL-6: Relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev. 53, 13–24 (2020).
doi: 10.1016/j.cytogfr.2020.05.009
pubmed: 32475759
pmcid: 7237916
Orhan, S. et al. The effect of acute phase reactants on the survival of COVID-19 patients in intensive care. Progr. Nutr. 23(S2), e2021268 (2021).